The Effect of Zoledronic Acid on Patients With Osteoarthritis of the Hip

Summary

Hip Osteoarthritis (OA) is one of the most common diseases affecting the ageing population. No specific and safe treatment slowing the development of hip OA as reflected in reduced joint space narrowing has been developed so far. Implantation of hip prosthesis has been a great success, but is expensive and puts a great financial pressure on hospitals and national healthcare programs. It also poses risks of serious complications. Current non-surgical treatment options focus on pain management and physiotherapy. Bisphosphonates have been shown to exert multiple beneficial effects in OA. Animal studies have demonstrated that bisphosphonates protect against subchondral bone degradation and preserve articular cartilage in mice and rats with OA. In this study 70 participants will be treated with either Zoledronic Acid (a potent Bisphosphonate) or Placebo (Saltwater). Allocation will be random and both parties are blinded. The investigators hypothesis is that participants treated with Zoledronic acid will have less pain, and better function after 12 months. The results will be tested with functional and pain scores, and functional tests. The study team will also measure the effects on disease related quality of life, bone quality measurements and the effect on bone marrow lesions on MRI (magnetic resonance imaging) and histological examination

Timeline

Start

2020-03-02

Primary completion

2023-06-30

Completion

2024-06-30

Publications

• Background Sellam J, Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatol. 2010 Nov;6(11):625-35. doi: 10.1038/nrrheum.2010.159. Epub 2010 Oct 5.
• Background Prieto-Potin I, Largo R, Roman-Blas JA, Herrero-Beaumont G, Walsh DA. Characterization of multinucleated giant cells in synovium and subchondral bone in knee osteoarthritis and rheumatoid arthritis. BMC Musculoskelet Disord. 2015 Aug 27;16:226. doi: 10.1186/s12891-015-0664-5.
• Background Roelofs AJ, Thompson K, Ebetino FH, Rogers MJ, Coxon FP. Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr Pharm Des. 2010;16(27):2950-60. doi: 10.2174/138161210793563635.
• Background Moreau M, Rialland P, Pelletier JP, Martel-Pelletier J, Lajeunesse D, Boileau C, Caron J, Frank D, Lussier B, del Castillo JR, Beauchamp G, Gauvin D, Bertaim T, Thibaud D, Troncy E. Tiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament model. Arthritis Res Ther. 2011 Jun 21;13(3):R98. doi: 10.1186/ar3373.
• Background Khorasani MS, Diko S, Hsia AW, Anderson MJ, Genetos DC, Haudenschild DR, Christiansen BA. Effect of alendronate on post-traumatic osteoarthritis induced by anterior cruciate ligament rupture in mice. Arthritis Res Ther. 2015 Feb 16;17(1):30. doi: 10.1186/s13075-015-0546-0.
• Background Duarte JH. Osteoarthritis: alendronate treatment improves pathology in animal model of OA by blocking osteoclastic bone resorption. Nat Rev Rheumatol. 2014 Aug;10(8):446. doi: 10.1038/nrrheum.2014.107. Epub 2014 Jul 8. No abstract available.
• Background Siebelt M, Waarsing JH, Groen HC, Muller C, Koelewijn SJ, de Blois E, Verhaar JA, de Jong M, Weinans H. Inhibited osteoclastic bone resorption through alendronate treatment in rats reduces severe osteoarthritis progression. Bone. 2014 Sep;66:163-70. doi: 10.1016/j.bone.2014.06.009. Epub 2014 Jun 13.
• Background Permuy M, Guede D, Lopez-Pena M, Munoz F, Gonzalez-Cantalapiedra A, Caeiro JR. Effects of glucosamine and risedronate alone or in combination in an experimental rabbit model of osteoarthritis. BMC Vet Res. 2014 Apr 26;10:97. doi: 10.1186/1746-6148-10-97.
• Background Yu DG, Yu B, Mao YQ, Zhao X, Wang XQ, Ding HF, Cao L, Liu GW, Nie SB, Liu S, Zhu ZA. Efficacy of zoledronic acid in treatment of teoarthritis is dependent on the disease progression stage in rat medial meniscal tear model. Acta Pharmacol Sin. 2012 Jul;33(7):924-34. doi: 10.1038/aps.2012.28. Epub 2012 May 21.
• Background Bagi CM, Berryman E, Zakur DE, Wilkie D, Andresen CJ. Effect of antiresorptive and anabolic bone therapy on development of osteoarthritis in a posttraumatic rat model of OA. Arthritis Res Ther. 2015 Nov 6;17:315. doi: 10.1186/s13075-015-0829-5.
• Background Buckland-Wright JC, Messent EA, Bingham CO 3rd, Ward RJ, Tonkin C. A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients. Rheumatology (Oxford). 2007 Feb;46(2):257-64. doi: 10.1093/rheumatology/kel213. Epub 2006 Jul 11.
• Background Walsh DA, McWilliams DF, Turley MJ, Dixon MR, Franses RE, Mapp PI, Wilson D. Angiogenesis and nerve growth factor at the osteochondral junction in rheumatoid arthritis and osteoarthritis. Rheumatology (Oxford). 2010 Oct;49(10):1852-61. doi: 10.1093/rheumatology/keq188. Epub 2010 Jun 26.
• Background Yoneda T, Hata K, Nakanishi M, Nagae M, Nagayama T, Wakabayashi H, Nishisho T, Sakurai T, Hiraga T. Involvement of acidic microenvironment in the pathophysiology of cancer-associated bone pain. Bone. 2011 Jan;48(1):100-5. doi: 10.1016/j.bone.2010.07.009. Epub 2010 Jul 14.
• Background Maas O, Joseph GB, Sommer G, Wild D, Kretzschmar M. Association between cartilage degeneration and subchondral bone remodeling in patients with knee osteoarthritis comparing MRI and (99m)Tc-DPD-SPECT/CT. Osteoarthritis Cartilage. 2015 Oct;23(10):1713-20. doi: 10.1016/j.joca.2015.05.014. Epub 2015 May 29.
• Background Shabestari M, Vik J, Reseland JE, Eriksen EF. Bone marrow lesions in hip osteoarthritis are characterized by increased bone turnover and enhanced angiogenesis. Osteoarthritis Cartilage. 2016 Oct;24(10):1745-1752. doi: 10.1016/j.joca.2016.05.009. Epub 2016 May 24.
• Background Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases. Med Oncol. 2008;25(3):346-9. doi: 10.1007/s12032-008-9043-5. Epub 2008 Jan 19.
• Background Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002 Sep;302(3):1055-61. doi: 10.1124/jpet.102.035295.
• Background Lampropoulou-Adamidou K, Dontas I, Stathopoulos IP, Khaldi L, Lelovas P, Vlamis J, Triantafillopoulos IK, Papaioannou NA. Chondroprotective effect of high-dose zoledronic acid: An experimental study in a rabbit model of osteoarthritis. J Orthop Res. 2014 Dec;32(12):1646-51. doi: 10.1002/jor.22712. Epub 2014 Aug 13.
• Background Dearmin MG, Trumble TN, Garcia A, Chambers JN, Budsberg SC. Chondroprotective effects of zoledronic acid on articular cartilage in dogs with experimentally induced osteoarthritis. Am J Vet Res. 2014 Apr;75(4):329-37. doi: 10.2460/ajvr.75.4.329.
• Background Rosa RG, Collavino K, Lakhani A, Delve E, Weber JF, Rosenthal AK, Waldman SD. Clodronate exerts an anabolic effect on articular chondrocytes mediated through the purinergic receptor pathway. Osteoarthritis Cartilage. 2014 Sep;22(9):1327-36. doi: 10.1016/j.joca.2014.07.009. Epub 2014 Jul 17.
• Background Richette P, Roux C. Impact of treatments for osteoporosis on cartilage biomarkers in humans. Osteoporos Int. 2012 Dec;23 Suppl 8:S877-80. doi: 10.1007/s00198-012-2165-9. Epub 2012 Nov 22.
• Background Bingham CO 3rd, Buckland-Wright JC, Garnero P, Cohen SB, Dougados M, Adami S, Clauw DJ, Spector TD, Pelletier JP, Raynauld JP, Strand V, Simon LS, Meyer JM, Cline GA, Beary JF. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum. 2006 Nov;54(11):3494-507. doi: 10.1002/art.22160.
• Background Nishii T, Tamura S, Shiomi T, Yoshikawa H, Sugano N. Alendronate treatment for hip osteoarthritis: prospective randomized 2-year trial. Clin Rheumatol. 2013 Dec;32(12):1759-66. doi: 10.1007/s10067-013-2338-8. Epub 2013 Jul 24.
• Background Varenna M, Zucchi F, Failoni S, Becciolini A, Berruto M. Intravenous neridronate in the treatment of acute painful knee osteoarthritis: a randomized controlled study. Rheumatology (Oxford). 2015 Oct;54(10):1826-32. doi: 10.1093/rheumatology/kev123. Epub 2015 May 20.
• Background Varenna M, Zucchi F, Failoni S, Becciolini A, Berruto M. Comment on: Intravenous neridronate in the treatment of acute painful knee osteoarthritis: a randomized controlled study: reply. Rheumatology (Oxford). 2015 Nov;54(11):2117-8. doi: 10.1093/rheumatology/kev302. Epub 2015 Sep 2. No abstract available.
• Background Rossini M, Adami S, Fracassi E, Viapiana O, Orsolini G, Povino MR, Idolazzi L, Gatti D. Effects of intra-articular clodronate in the treatment of knee osteoarthritis: results of a double-blind, randomized placebo-controlled trial. Rheumatol Int. 2015 Feb;35(2):255-63. doi: 10.1007/s00296-014-3100-5. Epub 2014 Aug 1.
• Background Laslett LL, Kingsbury SR, Hensor EM, Bowes MA, Conaghan PG. Effect of bisphosphonate use in patients with symptomatic and radiographic knee osteoarthritis: data from the Osteoarthritis Initiative. Ann Rheum Dis. 2014 May;73(5):824-30. doi: 10.1136/annrheumdis-2012-202989. Epub 2013 Apr 12.
• Background Laslett LL, Dore DA, Quinn SJ, Boon P, Ryan E, Winzenberg TM, Jones G. Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial. Ann Rheum Dis. 2012 Aug;71(8):1322-8. doi: 10.1136/annrheumdis-2011-200970. Epub 2012 Feb 21.
• Background Huskisson EC. Measurement of pain. Lancet. 1974 Nov 9;2(7889):1127-31. doi: 10.1016/s0140-6736(74)90884-8. No abstract available.
• Background Duarte Sosa D, Vilaplana L, Guerri R, Nogues X, Wang-Fagerland M, Diez-Perez A, F Eriksen E. Are the High Hip Fracture Rates Among Norwegian Women Explained by Impaired Bone Material Properties? J Bone Miner Res. 2015 Oct;30(10):1784-9. doi: 10.1002/jbmr.2537. Epub 2015 May 21.
• Background Duarte Sosa D, Fink Eriksen E. Women with previous stress fractures show reduced bone material strength. Acta Orthop. 2016 Dec;87(6):626-631. doi: 10.1080/17453674.2016.1198883. Epub 2016 Jun 20.
• Background Dobson F, Hinman RS, Hall M, Marshall CJ, Sayer T, Anderson C, Newcomb N, Stratford PW, Bennell KL. Reliability and measurement error of the Osteoarthritis Research Society International (OARSI) recommended performance-based tests of physical function in people with hip and knee osteoarthritis. Osteoarthritis Cartilage. 2017 Nov;25(11):1792-1796. doi: 10.1016/j.joca.2017.06.006. Epub 2017 Jun 22.
• Background Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, Brown C, Cooke TD, Daniel W, Feldman D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum. 1991 May;34(5):505-14. doi: 10.1002/art.1780340502.
• Background Miller PD. The kidney and bisphosphonates. Bone. 2011 Jul;49(1):77-81. doi: 10.1016/j.bone.2010.12.024. Epub 2011 Jan 11.
• Background Cipriani C, Pepe J, Clementelli C, Manai R, Colangelo L, Fassino V, Nieddu L, Minisola S. Effect of a single intravenous zoledronic acid administration on biomarkers of acute kidney injury (AKI) in patients with osteoporosis: a pilot study. Br J Clin Pharmacol. 2017 Oct;83(10):2266-2273. doi: 10.1111/bcp.13332. Epub 2017 Jun 27.
• Background Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Econ. 2018 Jan;27(1):7-22. doi: 10.1002/hec.3564. Epub 2017 Aug 22.

Drugs

Indications